Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · Invesco

Invesco Pharmaceuticals ETF (PJP)

Ticker PJP · Since 2005-06-23 · · Holdings as of Jul 31, 2026

Expense ratio
0.58%$58/yr per $10k
5-yr return
+9.0%annualized
1-yr return
+27.9%as of Dec 2025
Net assets
$472.1Mall share classes
Holdings
33

Bottom line

Is PJP a good fund? The bottom line

PJP is an actively managed health care sector ETF from Invesco.

Its expense ratio is 0.58% — about $58 a year on every $10,000 invested, cheaper than 79% of health care sector funds we track.

It returned +27.9% over one year, +9.0% a year over five years, +5.1% a year over ten (as of Dec 31, 2025, per its prospectus).

With $472 million in net assets and 33 holdings, its largest position is Invesco Private Prime Fund (7.9%) and the top 10 make up 53.7% of the portfolio.

What stands out

  • Low cost: cheaper than 79% of health care sector peers
  • 5-year return beat 96% of category peers

What to watch

  • Concentrated: top 10 holdings are 53.7% of assets

Updated Nov 19, 2026

What PJP invests in

The Invesco Pharmaceuticals ETF (the Fund) seeks to track the investment results (before fees and expenses) of the Dynamic Pharmaceutical Intellidex Index (the Underlying Index).

The Fund is an index fund that seeks to track the investment results of the Underlying Index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC (ICE Data or the Index Provider) compiles and maintains the Underlying Index, which is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. In accordance with the Underlying Index methodology, the various types of companies may include companies from the following segments of the pharmaceutical industry: ? Big Pharmaceutical: Large, vertically integrated drug companies that actively participate in all major phases of the drug development process, including research and development, animal and human testing, manufacturing and sales and marketing. ?…

From the fund's prospectus (filed Aug 27, 2026).

PJP performance

Fund calendar-year total returns, 2015–2025 2015: +11.1%; 2016: −19.3%; 2017: +15.3%; 2018: −1.7%; 2019: +4.7%; 2020: +11.2%; 2021: +14.5%; 2022: −2.0%; 2023: −2.2%; 2024: +9.7%; 2025: +27.9% +11% 2015 −19% 2016 +15% 2017 −2% 2018 +5% 2019 +11% 2020 +14% 2021 −2% 2022 −2% 2023 +10% 2024 +28% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
PJP+27.9%+9.0%+5.1%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full PJP performance history →

What PJP costs

On a $10,000 investment, PJP's 0.58% expense ratio costs about $58 a year. The prospectus estimates $726 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full PJP fee table →

PJP top 10 holdings

#Holding% of fund
1Invesco Private Prime Fund7.93%
2Abbott Laboratories5.67%
3AbbVie Inc.5.48%
4Amgen Inc.5.33%
5Johnson & Johnson5.18%
6Merck & Co., Inc.5.06%
7Eli Lilly and Co.5.02%
8Corcept Therapeutics Inc.4.96%
9Gilead Sciences, Inc.4.53%
10Pfizer Inc.4.50%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 53.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to PJP

More funds like PJP →

PJP FAQ

What is the expense ratio of PJP?
PJP's expense ratio is 0.58%, which works out to about $58 a year for every $10,000 invested. The prospectus estimates total costs of $726 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PJP a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 79% of health care sector peers; 5-year return beat 96% of category peers; concentrated: top 10 holdings are 53.7% of assets. This is general information, not personalized advice.
What does PJP hold?
PJP's largest holdings are Invesco Private Prime Fund (7.9%), Abbott Laboratories (5.7%), AbbVie Inc. (5.5%), Amgen Inc. (5.3%), Johnson & Johnson (5.2%). It holds 33 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is PJP's 5-year return?
PJP returned +9.0% a year over the five years ending Dec 31, 2025, and +5.1% a year over ten years. Past performance does not guarantee future results.
Who manages PJP?
PJP is offered by Invesco through Invesco Exchange-traded Fund Trust.